Tabalumab

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.[1][2] Tabalumab was developed by Eli Lilly and Company.

Tabalumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetBAFF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6518H10008N1724O2032S38
Molar mass146.25 kg/mol g·mol−1
 NY (what is this?)  (verify)

A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.[3] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.[4]

References
  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
  2. http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx
  3. http://lilly.mediaroom.com/index.php?s=9042&item=136985
  4. http://www.genengnews.com/gen-news-highlights/lilly-halts-tabalumab-development-for-lupus/81250423/


Now dropped by Lilly due to lack of efficacy.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.